Abstract
A randomised controlled trial (RCT) is considered the hierarchical peak of evidence-based medicine and a general demand for any result to be evaluated by RCTs has evolved. Yet, many advances in operative surgery do not result from RCTs and many controversies remain without an RCT being conducted. A randomised comparison of laparoscopic versus open liver resection has recently been called for. Using such a trial and others as examples, we examine the limitations of randomised design in skill-dependant interventions. Surgical procedures are skill-dependant, constantly developing, irreversible and traumatising. Additionally, placebo control is usually unethical and adequate blinding difficult or impossible to accomplish. Under these circumstances, surgeon and patient participation will be problematic and the resulting data will tend to have low external validity. While some of these obstacles can be modified, others will remain. Nonrandomised, prospective cohort comparison has other weaknesses, but may add complementary data with good external validity. An alternative hierarchy of evidence is warranted in this field.
Reviews on Recent Clinical Trials
Title:Randomised Trials in Surgery: The Burden of Evidence
Volume: 7 Issue: 3
Author(s): Kristoffer Lassen, Anne Hoye and Truls Myrmel
Affiliation:
Abstract: A randomised controlled trial (RCT) is considered the hierarchical peak of evidence-based medicine and a general demand for any result to be evaluated by RCTs has evolved. Yet, many advances in operative surgery do not result from RCTs and many controversies remain without an RCT being conducted. A randomised comparison of laparoscopic versus open liver resection has recently been called for. Using such a trial and others as examples, we examine the limitations of randomised design in skill-dependant interventions. Surgical procedures are skill-dependant, constantly developing, irreversible and traumatising. Additionally, placebo control is usually unethical and adequate blinding difficult or impossible to accomplish. Under these circumstances, surgeon and patient participation will be problematic and the resulting data will tend to have low external validity. While some of these obstacles can be modified, others will remain. Nonrandomised, prospective cohort comparison has other weaknesses, but may add complementary data with good external validity. An alternative hierarchy of evidence is warranted in this field.
Export Options
About this article
Cite this article as:
Lassen Kristoffer, Hoye Anne and Myrmel Truls, Randomised Trials in Surgery: The Burden of Evidence, Reviews on Recent Clinical Trials 2012; 7 (3) . https://dx.doi.org/10.2174/157488712802281402
DOI https://dx.doi.org/10.2174/157488712802281402 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adrenergic Receptors as Targets for Cancer Treatment - A Perspective for Future Studies
Current Cancer Therapy Reviews Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
Current Drug Targets Anti-Cancer Effect of α-Solanine by Down-Regulating S100P Expression in Colorectal Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery MiR-492 as an Important Biomarker for Early Diagnosis and Targeted Treatment in Different Cancers
Current Cancer Therapy Reviews Extra-telomeric Functions of Human Telomerase: Cancer, Mitochondria and Oxidative Stress
Current Pharmaceutical Design Recombinant Antibodies in Cancer Therapy
Current Protein & Peptide Science Strategies to Improve the Efficacy of Platinum Compounds
Current Medicinal Chemistry Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature
Current Medicinal Chemistry From Nanotechnology to Nanomedicine: Applications to Cancer Research
Current Molecular Medicine P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update
Current Drug Metabolism Exosomes and Lung Cancer: Roles in Pathophysiology, Diagnosis and Therapeutic Applications
Current Medicinal Chemistry Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry Predicting Cancer-Related MiRNAs Using Expression Profiles in Tumor Tissue
Current Pharmaceutical Biotechnology Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?
Recent Patents on Biomarkers The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Current Drug Targets A Connecting Switch Among Aging, Diabetes and Tumor: Avenue Leading to Cancer Therapeutics
Current Cancer Therapy Reviews Herbal Medicine of the 21st Century: A Focus on the Chemistry, Pharmacokinetics and Toxicity of Five Widely Advocated Phytotherapies
Current Topics in Medicinal Chemistry Treatment of Estrogen Receptor-Positive Breast Cancer
Current Medicinal Chemistry A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design